Real-world study: drug reduction in children with allergic rhinitis and asthma receiving immunotherapy

Area of Science:

• Pediatric Allergy and Immunology
• Respiratory Medicine

Background:

• Limited research exists on reducing medication use after allergen immunotherapy (AIT) for house dust mites (HDMs) in children.
• Pharmacological treatment is a common management strategy for pediatric allergic rhinitis and asthma.

Purpose of the Study:

• To compare the reduction in pharmacological treatment between children receiving HDM AIT and those receiving only pharmacotherapy.
• To assess the frequency of complete drug discontinuation as a primary outcome.

Main Methods:

• A historical cohort study design was employed.
• The study included children diagnosed with rhinitis or asthma.
• Data were collected on medication usage and discontinuation rates.

Main Results:

• Complete drug reduction was significantly higher in the AIT group (n=987) compared to the pharmacotherapy group (n=2012).
• For rhinitis, the 4-year cumulative incidence of 100% drug reduction was 30% in the AIT group versus 10.7% in the pharmacotherapy group.
• For asthma, the incidence was 24.1% in the AIT group versus 10.5% in the pharmacotherapy group.

Conclusions:

• HDM allergen immunotherapy is linked to a substantial decrease in pharmacotherapy requirements for children.
• This reduction in medication use serves as an indicator of improved clinical control.
• The findings suggest potential positive economic implications associated with AIT.